Verzenio showed promising efficacy in high-grade meningiomas with CDK pathway or NF2 alterations, achieving progression-free survival at six months in 14 of 24 patients. Patients with NF2 alterations ...
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas that have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results